Results 41 to 50 of about 23,326 (221)

Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis

Allergology International, 2023
Background: Eosinophilic otitis media (EOM) is a refractory condition associated with eosinophilic chronic rhinosinusitis and bronchial asthma. EOM is characterized by type-2 inflammation and is refractory to various treatments.
Daiki Nakashima, Tsuguhisa Nakayama, Syunsuke Minagawa, Tetsuya Adachi, Chieko Mitsuyama, Yoko Shida, Tsuneya Nakajima, Shin-ichi Haruna, Yoshinori Matsuwaki   +8 more
doaj   +1 more source

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis [PDF]

, 2019
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
Castro, Mario, et al,, Maspero, Jorge F
core   +1 more source

Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways [PDF]

, 2015
BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease with limited treatment options. Several microarray experiments have been conducted on lesional/LS and non-lesional/NL AD skin to develop a genomic disease phenotype.
Ewald, David Adrian, Guttman-Yassky, Emma, Krueger, James G., Litman, Thomas, Malajian, Dana, Suárez-Fariñas, Mayte, Tian, Suyan, Wang, Tianjiao, Workman, Christopher T   +8 more
core   +2 more sources

Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators

World Allergy Organization Journal
Objective: Allergen immunotherapy (AIT) and dupilumab have been confirmed to improve symptoms of atopic dermatitis (AD); however, the precise immune mechanisms underlying their efficacy and whether they can elicit synergistic immune effects remain not ...
Jin Liu, MM, Lin Yang, MD, PhD, Qingxiu Xu, MD, Qing Jiang, PhD, Nan Huang, MD, Wenjing Li, PhD, Yaqi Yang, MD, Dongxia Ma, MD, Le Li, MM, Yangxue Fu, PhD, Hao Chen, PhD, Rongfei Zhu, MD, PhD   +11 more
doaj   +1 more source

Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]

, 2018
According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca, Caminati, Marco, Facciolongo, Nicola, Galeone, Carla, Menzella, Francesco, Ruggiero, Patrizia, Scelfo, Chiara   +6 more
core   +2 more sources

Incidence of Conjunctivitis and Keratitis Among Individuals with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab in the United States: a Cohort Study in Routine Care Based on Healthcare Claims

Dermatology and Therapy
Introduction In clinical trials of patients with atopic dermatitis (AD), conjunctivitis and keratitis occurred more frequently with dupilumab than placebo.
Jessica M. Franklin, Andrea F. Marcus, Ihtisham Sultan, Ashley Howell, Sarah-Jo Sinnott, Jeannette Green, Stephen Ezzy, Robert Gately, Rachel E. Sobel, Florence T. Wang   +9 more
doaj   +1 more source

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

Frontiers in Immunology, 2021
BackgroundBullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed.
Yihua Zhang, Qiuyun Xu, Lihong Chen, Jiawen Chen, Jing Zhang, Ying Zou, Ting Gong, Chao Ji   +7 more
doaj   +1 more source

Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab

World Allergy Organization Journal
Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear.This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose ...
Koremasa Hayama, M.D., Ph.D., Mana Ito-Watanabe, M.D., Ph.D., Hideki Fujita, M.D., Ph.D.   +2 more
doaj   +1 more source

Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation [PDF]

, 2016
Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe ...
Lim, Jonathan Chee Woei, Soo, Hon Liong, Stanslas, Johnson, Sulaiman, Ibrahim   +3 more
core   +1 more source

Conjunctivitis in patients with atopic dermatitis treated with dupilumab

Drugs in Context, 2020
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL- 13 are key cytokines in the immunopathogenesis of AD.
Sandra Ferreira, Tiago Torres
doaj   +1 more source